Rx News Connection: March 2021
Price $0.00
Credits 0.5
Format
Aimovig
Course Information
Target Audience
Pharmacist
Pharmacy Technician
Nurse
Author
Cherie Dillon
Associate Editor
Cherie Dillon
Associate Editor
James Chan
PharmD, PhD
James Chan
PharmD, PhD
Knowledge Level
General Overview
This activity will apply to a broad range of learning needs/pharmacy settings. It may include common disease state/therapy overivews and/or general pharmacy needs such as medication errors, immunizations, or law topics.
Learning Objectives
Discuss the use of semaglutide for weight loss in people who are overweight or obese.
Discuss recent drug approvals, updated drug therapy recommendations, and important clinical trial results that may have an impact on today's practitioners and patients.
Describe the risk of using erenumab in a patient who has high blood pressure.
State the indication for monoclonal antibody treatments that have received FDA authorization for use in patients with COVID-19.
Pharmacist
Pharmacist
- Discuss recent drug approvals, updated drug therapy recommendations, and important clinical trial results that may have an impact on today's practitioners and patients.
- State the indication for monoclonal antibody treatments that have received FDA authorization for use in patients with COVID- 19.
- Discuss the use of semaglutide for weight loss in people who are overweight or obese.
- Describe the risk of using erenumab in a patient who has high blood pressure.
Pharmacy Technician
Pharmacy Technician
- Discuss recent drug approvals, updated drug therapy recommendations, and important clinical trial results that may have an impact on today's practitioners and patients.
- State the indication for monoclonal antibody treatments that have received FDA authorization for use in patients with COVID- 19.
- Discuss the use of semaglutide for weight loss in people who are overweight or obese.
- Describe the risk of using erenumab in a patient who has high blood pressure.
Nurse
Nurse
- Discuss recent drug approvals, updated drug therapy recommendations, and important clinical trial results that may have an impact on today's practitioners and patients.
- State the indication for monoclonal antibody treatments that have received FDA authorization for use in patients with COVID- 19.
- Discuss the use of semaglutide for weight loss in people who are overweight or obese.
- Describe the risk of using erenumab in a patient who has high blood pressure.
Course Accreditation
-
Activity Type:
Application -
Financial Support By:
PharmCon -
CE Broker
870784 -
Universal Activity Number:
Nurse : 0798-9999-21-162-H01-N
Pharmacy Technician : 0798-9999-21-162-H01-T
Pharmacist : 0798-9999-21-162-H01-P
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.
In order to obtain a Statement of Credit, attendees must answer poll questions where presented and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.
Technology Requirements
Hardware Requirements
Standard Windows/Mac System
iPad or iPhone
Minimum screen resolution: 1024x768
Speakers or headphones
Standard Windows/Mac System
iPad or iPhone
Minimum screen resolution: 1024x768
Speakers or headphones
Software Requirements
Standard Windows/Mac System
iPad or iPhone
Minimum screen resolution: 1024x768
Speakers or headphones
Standard Windows/Mac System
iPad or iPhone
Minimum screen resolution: 1024x768
Speakers or headphones
Network Requirements
Broadband Internet Connection:
T1, Hi-speed DSL or Cable
4G cellular connection
Broadband Internet Connection:
T1, Hi-speed DSL or Cable
4G cellular connection
Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.